Nanjing Vcare Won the 10th Place in the "Top 20 Chinese Pharmaceutical CRO Enterprises in 2023"

2023-06-26

Keep going with determination and reach far, and get another honor. Recently, the "2023 Ranking List of Chinese Pharmaceutical CRO Enterprises" was grandly released and awards were ceremoniously presented at the "2023 High-Quality Development Conference of the Big Health Industry and the 8th China Pharmaceutical R&D and Innovation Summit".

 

Nanjing Vcare PharmaTech Co., Ltd. ("Nanjing Vcare") was listed on the "Top 20 Chinese Pharmaceutical CRO Enterprises" list and ranked 10th. Since 2020, Vcare has been on this list for the fourth consecutive time, marking that its R&D strength, professional level, innovation ability and growth level have once again been affirmed and recognized by the industry.

Nanjing Vcare was established for the R&D and supply services of the whole CRO/CDMO industrial chain. It has always been focusing on the R&D and production services throughout the whole industrial chain and the whole life cycle of chemical drugs, and is committed to building a one-stop CRO/CDMO service platform integrating "chemistry + pharmacy + medicine" to accelerate and empower drug R&D. Nanjing Vcare has always adhered to innovation-driven development, keeping pace with the times and empowering innovation. We expect that on the road of facilitating the innovative development of the pharmaceutical industry, we can join hands with global pharmaceutical enterprises and new drug R&D institutions. In the integrated service chain of the whole industrial chain from pharmaceutical intermediates to active pharmaceutical ingredients for CDMO production and supply, and from pharmaceutical CMC to clinical CRO research and registration, we will provide differentiated customized services according to the needs of customers, achieve all-round technical and industrial support, and comprehensively help customers develop.

Prev

Nanjing Vcare Made an Appearance at CPHI China 2023

Next

Nanjing Vcare Was Successfully Selected as an "Innovative Small and Medium-sized Enterprise in Nanjing"